JNJ logo Johnson & Johnson +
Johnson & Johnson
+

Johnson & Johnson (JNJ) Business News

Track Johnson & Johnson in real time with a live news feed covering Johnson & Johnson stock news, official press releases, company announcements, and an archive of historical Johnson & Johnson news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection
12:20 PM | Monday | Aug 24, 2026 Business Wire

Louisiana Jury Issues $10 Million Verdict in Talc-Related Mesothelioma Case Against Johnson & Johnson

News Thumbnail
8:45 AM | Tuesday | Aug 4, 2026 Business Wire

Johnson & Johnson's Executive Vice President Jennifer Taubert to Retire; Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective September

News Thumbnail
8:30 AM | Thursday | Jul 30, 2026 PRNewsWire

Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer

News Thumbnail
8:30 AM | Thursday | Jul 23, 2026 PRNewsWire

TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma

News Thumbnail
7:00 AM | Wednesday | Jul 22, 2026 Business Wire

Johnson & Johnson Receives FDA Market Authorization in the U.S. for its OTTAVA™ Robotic Surgical System

News Thumbnail
8:11 AM | Thursday | Jul 16, 2026 Business Wire

Johnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Award

News Thumbnail
8:00 AM | Thursday | Jul 16, 2026 Business Wire

DePuy Synthes Acquires Expanding Innovations™

News Thumbnail
6:25 AM | Wednesday | Jul 15, 2026 Business Wire

Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2026

News Thumbnail
6:20 AM | Wednesday | Jul 15, 2026 Business Wire

Johnson & Johnson reports Q2 2026 results, raises 2026 outlook

News Thumbnail
7:45 AM | Wednesday | Jul 8, 2026 Business Wire

Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform

News Thumbnail

Louisiana Jury Issues $10 Million Verdict in Talc-Related Mesothelioma Case Against Johnson & Johnson

Business Wire

12:20 PM | Monday | Aug 24, 2026

news photo
Loading...

DALLAS--(BUSINESS WIRE)--Texas trial law firm Dean Omar Branham Shirley, LLP (DOBS) has secured a $10 million jury verdict in a mesothelioma case brought on behalf of the family of Lynne Roy, a Louisiana woman who died in 2020 after developing the deadly lung disease mesothelioma following decades of exposure to talc products. DOBS attorneys Danny Kraft and Darren McDowell led the trial team representing Ms. Roy and her family. After hearing testimony during a three-week trial in the Civil Dist.

Read full article redirect
12:20 PM | Monday | Aug 24, 2026

Louisiana Jury Issues $10 Million Verdict in Talc-Related Mesothelioma Case Against Johnson & Johnson

Business Wire

DALLAS--(BUSINESS WIRE)--Texas trial law firm Dean Omar Branham Shirley, LLP (DOBS) has secured a $10 million jury verdict in a mesothelioma case brought on behalf of the family of Lynne Roy, a Louisiana woman who died in 2020 after developing the deadly lung disease mesothelioma following decades of exposure to talc products. DOBS attorneys Danny Kraft and Darren McDowell led the trial team representing Ms. Roy and her family. After hearing testimony during a three-week trial in the Civil Dist.

Read full article arrow
News Thumbnail
8:45 AM | Tuesday | Aug 4, 2026

Johnson & Johnson's Executive Vice President Jennifer Taubert to Retire; Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective September

Business Wire

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced that Jennifer Taubert will retire from her position as Executive Vice President, Worldwide Chairman, Innovative Medicine following a distinguished career and over 21-year tenure at Johnson & Johnson. Under her leadership, the Company's Innovative Medicine business grew to more than $60 billion in annual revenue and strengthened its position as one of the most respected and successful pharmaceutical busin.

Read full article arrow
News Thumbnail
8:30 AM | Thursday | Jul 30, 2026

Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer

PRNewsWire

Priority Review reinforces the significant potential of subcutaneous amivantamab in recurrent or metastatic head and neck cancer, where the current five-year survival rate is only 15 percent  Patients achieved rapid, deep and durable responses, including a 42 percent overall response rate with one-third achieving a complete response  Subcutaneous amivantamab is the only therapy in head and neck cancer engineered to target both EGFR and MET, proven drivers of tumor growth and treatment resistance RARITAN, N.J., July 30, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the supplemental Biologics License Application (sBLA) for subcutaneous amivantamab and hyaluronidase-lpuj for adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).

Read full article arrow
News Thumbnail
8:30 AM | Thursday | Jul 23, 2026

TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma

PRNewsWire

Investigational MonumenTAL-6 trial is the first and only Phase 3 study of a dual antigen, BCMA and GPRC5D targeting regimen in relapsed/refractory multiple myeloma Fifth positive Phase 3 study evaluating Johnson & Johnson's multiple myeloma T-cell therapy portfolio in second line, further strengthening the company's leadership and commitment to advancing immunotherapy-based regimens earlier in the treatment journey RARITAN, N.J., July 23, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ), a worldwide leader in multiple myeloma therapies, today announced positive topline results from the three-arm investigational Phase 3 MonumenTAL-6 study evaluating TECVAYLI® (teclistamab-cqyv) + TALVEY® (talquetamab-tgvs), a BCMA and GPRC5D dual antigen targeting regimen, and TALVEY® + pomalidomide in adult patients with relapsed or refractory multiple myeloma (RRMM) who received 1 to 4 prior lines of therapy, including an anti-CD38 antibody and... Read more

Read full article arrow
News Thumbnail
7:00 AM | Wednesday | Jul 22, 2026

Johnson & Johnson Receives FDA Market Authorization in the U.S. for its OTTAVA™ Robotic Surgical System

Business Wire

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has granted De Novo authorization for the OTTAVA™ Robotic Surgical System, the world's first table-integrated soft tissue robotic system.
The system received marketing authorization for multiple procedures in general surgery, including Roux-en-Y gastric bypass, gastrectomy, cholecystectomy, splenectomy, gastric sleeve, small bowel resection, appendectomy, lysis of adhesio.

Read full article arrow
News Thumbnail
8:11 AM | Thursday | Jul 16, 2026

Johnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Award

Business Wire

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced with TIME the launch of the Healthcare Champion of the Year. The new branded recognition will honor healthcare professionals in the U.S.
, selected by Johnson & Johnson and a panel of industry experts, whose care, innovation and grit are driving health system change to advance better care for all. Nominations for the inaugural TIME Healthcare Champion of the Year, in partnership with Johnson & Johnson.

Read full article arrow
News Thumbnail
8:00 AM | Thursday | Jul 16, 2026

DePuy Synthes Acquires Expanding Innovations™

Business Wire

RAYNHAM, Mass.--(BUSINESS WIRE)--DePuy Synthes, a global leader in orthopaedic technologies and solutions, today announced it has acquired Expanding Innovations, Inc., an emerging leader in expandable implant technology for spine surgery. The transaction strengthens DePuy Synthes' Spine portfolio and expands its position in the rapidly growing expandable interbody cage segment. Expanding Innovations (EI) is a commercial-stage medical technology company focused on developing and commercializing.

Read full article arrow
News Thumbnail
6:25 AM | Wednesday | Jul 15, 2026

Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2026

Business Wire

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2026 of $1.34 per share on the company's common stock. The dividend is payable on September 8, 2026 to shareholders of record at the close of business on August 25, 2026.
The ex-dividend date is August 25, 2026. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare inn.

Read full article arrow
News Thumbnail
6:20 AM | Wednesday | Jul 15, 2026

Johnson & Johnson reports Q2 2026 results, raises 2026 outlook

Business Wire

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2026. “Johnson & Johnson delivered strong second-quarter results, demonstrating the power of our innovation, the depth of our portfolio and the momentum in our pipeline as we advance transformative treatments that address the world's toughest health challenges,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. “With raised guidance and quarterly.

Read full article arrow
News Thumbnail
7:45 AM | Wednesday | Jul 8, 2026

Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform

Business Wire

IRVINE, Calif.--(BUSINESS WIRE)--Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform.

Read full article arrow
News Thumbnail